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IGF-binding protein-3 (IGFBP-3) is the major circulating carrier protein for IGF, and also acts as a
potent antiproliferativeagent in various cell types. Recently, IGFBP-3was reported tomediatehigh
glucose-induced apoptosis inmesangial cells and podocytes. In this study, we investigated the role
of IGFBP-3 in high glucose-induced apoptosis in proximal tubular epithelial cells (PTEC). Expression
of IGFBP-3 protein and mRNA in a porcine PTEC line (LLC-PK1 cells) was measured after exposure
to either standard (5.5 mM) or high-glucose (30 mM) medium.We quantified apoptosis after treat-
mentwith small interferingRNAagainst IGFBP-3 (siRNA:IGFBP-3) inhigh-glucosemediumor in cells
that overexpressed IGFBP-3. Oxidative stress was measured in high-glucose medium, in the pres-
ence of siRNA:IGFBP-3, or in IGFBP-3-overexpressing cells. IGFBP-3 protein andmRNAexpression in
LLC-PK1 cells was higher in high-glucose medium than in standard-glucose medium. Exposure to
high-glucose medium increased apoptosis, and high-glucose-induced apoptosis was abolished by
siRNA:IGFBP-3. IGFBP-3 overexpression induced apoptosis in LLC-PK1 cells. Both high-glucose
medium and IGFBP-3 overexpression increased reactive oxygen species, and siRNA:IGFBP-3
reduced this increase. Antioxidant treatment decreased IGFBP-3 expression and apoptosis,
whereas oxidative stress from hydrogen peroxide increased IGFBP-3 expression, suggesting
that oxidative stress increases IGFBP-3 expression. Our results suggest that increased IGFBP-3
expression by high glucose mediates high-glucose-induced apoptosis in PTEC. Increased oxi-
dative stress from high glucose enhances IGFBP-3 expression, inducing apoptosis. Increased
expression of IGFBP-3 by high glucose induces additional oxidative stress, which may result in
amplification of hyperglycemic damage. (Endocrinology 152: 3135–3142, 2011)
Diabetic nephropathy is the leading cause of end-stagerenal disease (1). The pathophysiological mechanism
of the development and progression of diabetic nephrop-
athy has been studied extensively over the past few de-
cades. The pathways that may be involved include in-
creased oxidative stress, accumulation of advanced
glycation end-product (AGE), and activation of intracel-
lular signalingmolecules such as protein kinase C (2). Hy-
perglycemia increases the expression of growth factors
and cytokines, whichmay directly or indirectly contribute
to the renal changes seen in diabetes (3, 4).
IGF-binding protein-3 (IGFBP-3) is a component of the
IGF-IGFBP axis and major carrier protein for IGF.
IGFBP-3has intrinsic biological activity aswell as the abil-
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ity to bind and sequester active IGF hormones, thereby
modulating their bioactivity (5, 6). IGFBP-3 has a role as
a potent IGF-IGF receptor-independent antiproliferative
agent in various cell types, and acts by blocking the cell
cycle and inducing apoptosis (7–9). In addition, IGFBP-3
may contribute to insulin resistance in adipocytes (10, 11)
and inhibit adipocyte differentiation (12).
Apoptosis is rarely observed in the normal kidney but
is reported in renal diseases including renal ischemia-rep-
erfusion injury (13) and chronic renal failure (14). In di-
abetic rats, apoptosis increases in renal tubular and inter-
stitial cells, and this is reversed by insulin therapy (15).
Apoptosis also occurs in the human diabetic kidney, es-
pecially in the tubular epithelial cells (16). Although high
ambient glucose induces mesangial IGF signaling and cel-
lular hypertrophy, high glucose also induces programmed
mesangial cell death in vitro by apoptosis (17).
IGFBP-3may contribute to the pathogenesis of diabetic
nephropathy by modulating the bioactivity of IGF via an
IGF-dependent mechanism and by inducing apoptosis in
kidney cells via both IGF-independent and IGF-dependent
mechanisms (5). IGFBP-3 is reported to increase mesan-
gial cell apoptosis under high ambient or standard levels of
glucose, and an antisense IGFBP-3 oligodeoxynucleotide
inhibits apoptosis induced by high glucose or by TNF-
(18). Recent human biopsy studies have proposed evi-
dence that podocytes are functionally and structurally in-
jured very early in the natural history of diabetic nephrop-
athy (19). Exogenous IGFBP-3 induces IGF-independent
podocyte apoptosis (5).
Both the glomerular and tubular compartmentsmay be
involved in the development of diabetic nephropathy. The
proximal tubule plays a crucial role in the pathogenesis of
diabetic kidney disease and is susceptible to a variety of
metabolic and hemodynamic factors associated with dia-
betes, especially hyperglycemia. Glucose entry into prox-
imal tubular epithelial cells (PTEC) is insulin independent,
which makes PTEC particularly sensitive to the deleteri-
ous effects of chronic hyperglycemia, and the proximal
tubules react with tubular hypertrophy, tubular atrophy,
and reduced organic ion transport (20, 21). Tubulointer-
stitial pathology, rather than glomerular pathology, cor-
relates with renal dysfunction in diabetic nephropathy
(20, 22).
Because the kidney has marked heterogeneity in cell
populations, in vitro studies in individual renal cell types
are essential.However, no study has focused on the role of
IGFBP-3 in high-glucose-induced apoptosis in PTEC. In
this study, we investigated IGFBP-3 expression and apo-
ptosis in PTEC exposed to high-glucose medium, along
with the specific role of IGFBP-3 in PTEC apoptosis. To
investigate the mechanism of IGFBP-3-mediated PTEC
apoptosis in high-glucose medium, we also studied the




TheLLC-PK1 cells, a porcine PTEC line that does not contain
any virus or oncogene for immortalization, was purchased from
the American Type Culture Collection (Rockville, MD). LLC-
PK1 cellswere grown in 75-cm3 tissue culture flasks inLifeTech-
nologies, Inc. Medium 199 (Invitrogen, Carlsbad, CA). Subcon-
fluent cells were harvested and seeded into 100-mm dishes in 10
ml growth medium and allowed to adhere for 18 h in a humid-
ified incubator at 37 C with 5% CO2 in air.
Establishment of IGFBP-3-overexpressing PTEC line
An IGFBP-3-overexpressing LLC-PK1 cell line was estab-
lished by transfection of IGFBP-3 cDNA containing 1.5-kb hu-
man IGFBP-3 (equivalent to 133-1008 in the cDNA sequence),
ligated into thepCMV6vector.TransfectionusedLipofectamine
2000 (Invitrogen). After 48 h, cells were split into selective me-
dium containing G418 (800 g/ml) for pCMV6/IGFBP-3, and
foci were picked to generate a stable cell line.
Overexpression of GGG-IGFBP-3, a mutant IGFBP-3 that
cannot bind to IGF, was also performed to verify the IGF-inde-
pendent effect of IGFBP-3 on apoptosis in LLC-PK1 cells. The
GGG-IGFBP-3 mutant cDNA was generated by site-directed
mutagenesis at residues Ile 56, Leu 80, and Leu 81 toGly 56, Gly
80, and Gly 81, as described previously (23). Binding studies,
including BIAcore analysis, showed that the GGG-IGFBP-3mu-
tant protein, generated in Escherichia coli and baculovirus ex-
pression systems, lacks affinity for IGF (23).
Small interfering RNA transfection
Small interfering RNA against IGFBP-3 (siRNA:IGFBP-3,
siGENOME SMARTpool M-004777-01-0005), and mismatch
control (ON-TARGETplus siCONTROL, D-001810-01-05)
were from Dharmacon Research (Lafayette, CO), and 12.5 nM
siRNA:IGFBP-3 was transfected as above. Cells were incubated
in growth medium with 10% fetal bovine serum for 24 h.
Reagents and antibodies
Antihuman IGFBP-3 antibody was from AbCam (Cam-
bridge, MA). Horseradish peroxidase-labeled IgG (1:3000;
Santa Cruz Biotechnology, Santa Cruz, CA) was used for sec-
ondary antibody. Primer pairs for real-time PCRwere from Ap-
plied Biosystems (HS-00181211-m1 for IGFBP-3, Hs99999903
for -actin).
Annexin V-fluorescein isothiocyanate (FITC) apoptosis de-
tection kits were from R&D Systems (Minneapolis, MN), and
the cellular DNA fragmentation ELISA kit was from Roche Di-
agnostics (Mannheim, Germany). The cell-permeable fluoro-
genic probe dichlorodihydrofluorescein diacetate (DCF-DA),
and the antioxidants, N-acetyl-L-cysteine (NAC) and glutathi-
one (GSH) were from Sigma-Aldrich (St. Louis, MO).
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Western blot analysis
LLC-PK1cellswere analyzedafter 72h exposure to standard-
glucose (5.5mM) or high-glucose (30mM)medium. ForWestern
blots, 20lmedium fromLLC-PK1 cellswas electrophoresed on
11% acrylamide gels in the presence of sodium dodecyl sulfate
and electroblotted onto polyvinylidene fluoride membranes. Af-
ter blocking 1 h with 5% wt/vol skim milk, membranes were
incubated overnight at 4 C with antihuman IGFBP-3 antibody.
Secondary antibody was horseradish peroxidase-labeled IgG (1:
3000), and detection was by enhanced chemiluminescence (Am-
ersham Biosciences, Little Chalfont, UK).
RT-PCR and real-time quantitative PCR
RT-PCR and real-time quantitative PCRwere performed us-
ing whole-cell lysates from LLC-PK1 cells after 48 h exposure to
standard- or high-glucosemedium. In brief,
total RNAwas isolated usingTrizol reagent
(Invitrogen) and 2 g total RNA subjected
to reverse transcription using a Superscript
III first-strand synthesis system (Invitrogen)
with primers for RT-PCR[(IGFBP-3 (up):
aaatggagga cacgctgaac, IGFBP-3 (down):
tacttatcca cgcaccagca], according to the
manufacturer’s instructions.
Amplificationwas induplicate, using the
ABI 7300 system (Applied Biosystems, Fos-
ter City, CA) with the following profile: 94
C for 5 min, 35 cycles of 95 C for 30 sec, 50
C for 30 sec, and 72 C for 30 sec, followed
by 72 C for 10 min.
Real-time quantitative PCRwaswith 20
l PCR amplification reactionmixture con-
taining DNA, TaqMan primer pairs, and
TaqMan universal PCR master mix (Ap-
plied Biosystems). Amplification was in du-
plicate as above with the following profile:
50 C for 2 min, 95 C for 10 min, and 40
cycles of 95C for 15 secwith 60C for 1min.
Gene expression for each sample was ex-
pressed as cycle threshold (Ct) normalized
to-actin (Ct).Ct valueswere compared
between samples from high-glucose-treated
cells and control cells in serum-free me-
dium, forCt calculations. The final com-
parison of transcript ratios between sam-
ples is given as 2Ct.
Quantification of apoptosis by
annexin V-FITC staining
Subconfluent monolayers of LLC-PK1
cells were exposed to medium containing
either standard or high glucose for 72 h.
Detection of annexin V on the cell surface
was done using a flow cytometer (Bekman
Coulter Corp., Fullerton, CA). System II
software was used for acquisition and anal-
ysis. AnnexinV-FITC conjugate (R&DSys-
tems) was used to stain cells. In brief, cells
and supernatants were harvested, washed,
and incubated for 15 min with annexin V-
FITC and propidium iodide to differentiate
between early apoptotic cells (annexin V-
positive), late apoptotic and/or necrotic cells (annexin V and
propidium iodide positive), and viable cells (unstained). The sum
of early apoptotic and late apoptotic/necrotic cells were consid-
ered as total apoptotic cells and was used for statistical analysis.
Quantification of apoptosis by DNA fragmentation
Cells were prelabeled by incubation with 10 M bromode-
oxyuridine (BrdU) for 12 h at 37C. Labeled cells were incubated
in 5.5 or 30 mM glucose or 30 mM mannitol for an osmotic
control. After 48 h, cells were centrifuged, and the supernatant
was analyzed for apoptosis. After adsorbing anti-DNAantibody
onto the wells of a microplate, sample was added to the micro-
plate, allowing BrdU-labeled DNA fragments to bind to the im-
mobilized antibody. Immunocomplexed BrdU-labeled DNA-
FIG. 1. High glucose increased IGFBP-3 expression and apoptosis in LLC-PK1 cells, and IGFBP-
3 mediated high-glucose-induced apoptosis. A, Western blot of IGFBP-3 in standard and high-
glucose medium for 72 h with or without siRNA:IGFBP-3. Representative blot and means  SD
of six independent experiments are shown. B and C, RT-PCR (B) and real-time PCR (C)
showing increased IGFBP-3 mRNA expression after 48 h exposure to high-glucose medium
(n  4). D, Representative data and means  SD of annexin V-FITC staining showing increased
apoptosis in LLC-PK1 cells after 72 h exposure to high-glucose medium. High-glucose-induced
apoptosis was prevented by siRNA:IGFBP-3. The sum of early apoptotic (lower right) and late
apoptotic and/or necrotic cells (upper right) are presented (n  4). E, High glucose increased
DNA fragmentation compared with standard glucose and osmotic control. High-glucose-
induced apoptosis was prevented by treatment with siRNA:IGFBP-3 (n  3). *, P  0.05.
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fragments were denatured by microwave irradiation, and anti-
BrdU antibody peroxidase conjugate was added to form an
immunocomplex. Bound anti-BrdU-peroxidase was quantified
using an ELISA plate reader.
Oxidative stress measurement
The cell-permeable fluorogenic probe DCF-DA diffuses
across cell membranes and is hydrolyzed by nonspecific cellular
esterases to the nonfluorescent compound dichlorofluorescin
(DCFH), which is predominantly trapped within the cell. In the
presence of reactive oxygen species (ROS), DCFH rapidly un-
dergoes one-electron oxidation to the highly fluorescent com-
pound dichlorofluorescein (DCF).Our assaywas amodification
of the Bestwick andMilne (24) procedure. Glucose-exposed cell
monolayerswere incubatedwith10MDCF-DA inPBS (pH7.4)
for 15 min at 37C. Cells were washed once with PBS, and cell
debriswas cleared by centrifugation at 3000 rpm for 5min.Cells
were treated with trypsin and washed once with PBS, and cell
debris were cleared by centrifugation at 1000 rpm for 5 min.
Fluorescence was monitored using a flow cytometer as above,
using480-nmexcitation and530-nmemissionwavelengths. Flu-
orescent levels are expressed as the percent increase over the
control.
Data expression and statistical
analysis
Results of three ormore independent ex-
periments are expressed as mean SD. Sta-
tistical comparison among groupswere per-
formed using one-way ANOVA followed
by Tukey’s post hoc analysis. P 0.05 was
considered significant.
Results
High glucose increases IGFBP-3
expression in PTEC
We examined whether high glucose
increases IGFBP-3 expression in LLC-
PK1 cells. Western blots revealed that
IGFBP-3 protein is increased in LLC-
PK1 cells exposed to high-glucose me-
dium, compared with cells exposed to
standard-glucose medium (Fig. 1A).
IGFBP-3 expression was decreased in
LLC-PK1 cells in high-glucose medium
after cotreatmentwith siRNA:IGFBP-3
(Fig. 1A). IGFBP-3 mRNA expression
was also increased in cells in high glu-
cose, as measured by RT-PCR (Fig. 1B)
or real-timequantitativePCR(Fig. 1C).
To confirm the effect of high-glucose
medium on IGFBP-3 expression, we ex-
amined the expression of IGFBP-3 at
different glucose concentrations and
time courses. IGFBP-3 expressions in
30 and 45mM glucose media were sig-
nificantly increased compared with those in 5.5 mM glu-
cose medium (Supplemental Fig. 1, A and B, published
on The Endocrine Society’s Journals Online web site at
http://endo.endojournals.org). IGFBP-3 protein expres-
sion was significantly increased by 24 h exposure to high-
glucose medium, which was inhibited by siRNA:IGFBP-3
(Supplemental Fig. 1, C and D). IGFBP-3 mRNA expres-
sion was significantly increased after 12, 24, and 48 h
exposure to high-glucose medium, which was also effec-
tively inhibited by siRNA:IGFBP-3 (Supplemental Fig. 1,
E and F).
IGFBP-3 mediates high-glucose-induced apoptosis
in PTEC
Weinvestigatedwhether highglucose increases apoptosis
inLLC-PK1cells.AnnexinV-FITCstaining revealed that the
percentage of apoptotic cells in high-glucose medium was
higher than in standard-glucose medium (18.3  1.2 vs.
5.81.7%,P0.05), indicating thathighglucose increases
FIG. 2. IGFBP-3 overexpression increased apoptosis in LLC-PK1 cells. A, Western blot of
IGFBP-3 protein expression (n  6). B and C, RT-PCR (B) and real-time PCR (C) showing
increased IGFBP-3 mRNA expression (n  6). D, Annexin V-FITC staining showing increased
PTEC apoptosis by IGFBP-3 overexpression. GGG-IGFBP-3 overexpression also increased
apoptosis. Representative data and means  SD of four independent experiments are shown.
E, IGFBP-3 overexpression and exposure to high glucose increased apoptosis measured by
DNA fragmentation (n  3). *, P  0.05.
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apoptosis in LLC-PK1 cells (Fig. 1D). The apoptosis-induc-
ing effect of high glucosewas abolished by cotreatmentwith
siRNA:IGFBP-3, suggesting that IGFBP-3 mediates high-
glucose-induced apoptosis (Fig. 1D). Moreover, measure-
ment of apoptosis byDNA fragmentation demonstrated the
same pattern in LLC-PK1 cells in high glucose,with orwith-
out siRNA:IGFBP-3 (Fig. 1E). Treatment with 30mMman-
nitol did not increase apoptosis in LLC-PK1 cells (Fig. 1E),
suggesting that the increased apoptosis in high glucose did
not result from high osmolarity.
To confirm the effect of high-glucosemediumon PTEC
apoptosis, we performed annexin V-FITC staining under
different glucose concentrations and exposure time. Ap-
optosis in LLC-PK1 cells were significantly increased after
exposure to 15, 30, and 45 mM glucose media compared
with5.5mMglucosemedium.Because apoptosiswasmost
prominent in 30 mM glucose medium, we labeled 30 mM
glucose as a high-glucose condition throughout the exper-
iment (Supplemental Fig. 2A).Apoptosiswas significantly
increased inLLC-PK1 cells after 24, 48, and72h exposure
to high-glucose medium, which was most prominent at 72 h
(Supplemental Fig. 2B). Preincubation with siRNA:IGFBP-3
significantly inhibitedapoptosisafter12,24,and48hexposure
to high-glucose medium (Supplemental Fig. 2C).
IGFBP-3 overexpression increases apoptosis in
PTEC
To confirm the effect of increased IGFBP-3 expression
on apoptosis in LLC-PK1 cells, we established an IGFBP-
3-overexpressing PTEC line by transfectionwith IGFBP-3
cDNA. Figure 2, A–C, shows the increase in IGFBP-3 pro-
teinandmRNAin the IGFBP-3-overexpressingPTECline.
Annexin V-FITC staining showed that IGFBP-3 overex-
pression increased apoptosis (empty vector control, 8.1
0.7%, vs. IGFBP-3 overexpression, 21.8  4.2%; P 
0.01) (Fig. 2D). GGG-IGFBP-3 overexpression also in-
creased apoptosis (empty vector control, 8.1 0.7%, vs.
GGG-IGFBP-3 overexpression, 18.4  3.6%; P 0.01),
suggesting that IGFBP-3 promotes PTEC apoptosis in an
IGF-independent manner (Fig. 2D). Measurement of ap-
optosis by DNA fragmentation also demonstrated that
GGG-IGFBP-3 overexpression, as well as IGFBP-3 over-
expression, increased apoptosis (P 0.05 compared with
cells in standard glucose, Fig. 2E).
IGFBP-3 is involved in oxidative stress induction by
high glucose in PTEC
We investigated the effect of high glucose and IGFBP-3
expression on oxidative stress in LLC-PK1 cells. Exposure
to high-glucose medium increased oxidative stress, as
measured by DCF-DA staining (standard glucose, 9.7 
0.4%, vs. high glucose, 20.8 0.7%, P 0.01; Fig. 3A).
NAC andGSH, the antioxidants, prevented ROS increase
in high-glucose medium (P  0.01, Fig. 3A). ROS was
significantly increased by high glucose at 6 h, and treat-
ment with siRNA:IGFBP-3 reduced oxidative stress in
LLC-PK1 cells exposed to high-glucose medium (siRNA:
IGFBP-3 with high glucose, 7.2 2.9%, vs. high glucose
only, 18.2  4.6%, P  0.01; Fig. 3B). Moreover,
IGFBP-3 overexpression increased oxidative stress (empty
vector, 7.9  2.6%, vs. IGFBP-3 overexpression, 19.7 
2.7%, P  0.01; Fig. 3C), suggesting that IGFBP-3 is in-
volved in high-glucose-induced ROS generation in LLC-
PK1 cells.
FIG. 3. A, Exposure to high-glucose medium for 6 h increased
oxidative stress measured by DCF-DA fluorescence. NAC and GSH, the
antioxidants, prevented ROS increase by high-glucose medium (n  4).
B, ROS was significantly increased by high glucose at 6 h, and
treatment with siRNA:IGFBP-3 reduced oxidative stress in cells exposed
to high-glucose medium (n  4). C, IGFBP-3 overexpression increased
oxidative stress in LLC-PK1 cells (n  4). *, P  0.05.
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Oxidative stress increases IGFBP-3 expression and
mediates PTEC apoptosis
We further investigated the effect of oxidative stress on
IGFBP-3 expression and high-glucose-induced apoptosis
in LLC-PK1 cells. Preincubation with antioxidants NAC
and GSH abolished increase in IGFBP-3 protein expres-
sion by high-glucose media, whereas elevating oxidative
stress with hydrogen peroxide increased IGFBP-3 expres-
sion (Fig. 4A). IGFBP-3 mRNA expression was also re-
duced by NAC and GSH, whereas it was increased by
hydrogen peroxide (Fig. 4, B and C). These findings sug-
gest that increased oxidative stress by high glucose may
stimulate IGFBP-3 expression.
We also investigated whether antioxidant prevented
high-glucose-induced apoptosis in LLC-PK1 cells. An-
nexin V-FITC staining showed that NAC and GSH de-
creased apoptosis in high-glucose medium (NAC with
high glucose, 10.9  1.2%, and GSH with high glucose,
13.9  1.9%, vs. high glucose only,
20.2  4.0%, P  0.01; Fig. 4D).
Taken together, these results imply that
increased oxidative stress from high
glucose increased IGFBP-3 expression,
resulting in increased apoptosis.
Discussion
Chronic hyperglycemia is the central
initiating factor in diabetic nephropa-
thy. Although all diabetic cells are ex-
posed to elevated levels of plasma glu-
cose, most cells are able to reduce
glucose transport into the cell during
hyperglycemia, so that internal glucose
concentrations remain constant. In
contrast, in cells damaged by hypergly-
cemia, the glucose transport rate does
not decline rapidly during hyperglyce-
mia (2). PTEC, like mesangial cells and
podocytes, develop intracellular hyper-
glycemia, which can result in hypergly-
cemic damage (25). Samikkannu et al.
(26) demonstrated that acute exposure
of humanPTECtohighglucose induces
a time-dependent dual effect of early
proliferation and late apoptosis.
Cellular responses to high glucose
are numerous and varied but ultimately
result in functional changes and often
cell death. High glucose induces oxida-
tive and nitrosative stress, causing ac-
tivation of proteins involved in apopto-
tic cell death, which is important to the development of
diabetic complications (27). In this study, high-glucose
medium increased IGFBP-3 protein and mRNA levels in
PTEC. IGFBP-3 mRNA expression is reported to be in-
creased in the proximal tubules of diabetic rat kidney (28),
but few studies have reported on IGFBP-3 expression in
high-glucose medium in a PTEC line.
Initially, IGFBP-3was considered tomodulate only the
actions of circulating IGF, but it also exhibits clear, dis-
tinct biological effects independent of the IGF/IGF-I re-
ceptor (IGF-IR) axis. Apart from modulating IGF actions
(IGF/IGF-IR-dependent actions), IGFBP-3 clearly exerts
intrinsic bioactivity either in the absence of IGForwithout
triggering IGF-IR signaling (IGF/IGF-IR-independent ac-
tions) (6). IGFBP-3 inhibits growth and induces apoptosis
by both IGF-dependent and IGF-independent mecha-
nisms. GH and tumor suppressors such as p53 induce
FIG. 4. Effect of antioxidants (NAC and GSH) on IGFBP-3 expression and apoptosis. A,
Preincubation with 10 mM NAC for 15 min or 4 mM GSH for 30 min inhibited IGFBP-3
expression, whereas exposure to 0.1% hydrogen peroxide (H2O2) for 6 h increased IGFBP-3
expression. (n  6). B and C, RT-PCR (B) and real-time PCR (C) showing decreased IGFBP-3
mRNA after preincubation with NAC or GSH. Exposure to H2O2 increased IGFBP-3 mRNA (n 
4). D, Preincubation with NAC or GSH reduced PTEC apoptosis induced by high-glucose
conditions, as measured by annexin V-FITC staining (n  4). Representative blots and
means  SD of four experiments are shown. *, P  0.05.
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IGFBP-3 expression. Physiological stimuli, including
DNA damage by irradiation and hypoxia, are reported to
induce IGFBP-3, suggesting that IGFBP-3 is involved in
physiological protectionagainst aberrant cell growth (29).
In this study, high glucose increased IGFBP-3 expres-
sion and apoptosis in PTEC, and high-glucose-induced
apoptosis was abolished by cotreatment with siRNA:
IGFBP-3, suggesting that IGFBP-3mediates high-glucose-
induced apoptosis in PTEC. In addition, IGFBP-3 over-
expression increased PTEC apoptosis. Moreover,
overexpression of GGG-IGFBP-3, a mutant IGFBP-3 that
cannot bind to IGF, also increased apoptosis. These find-
ings suggest that increased IGFBP-3 by high glucose in-
duces PTEC apoptosis, at least partly by an IGF-indepen-
dent mechanism. Although similar results have been
reported in mesangial cells (18) and podocytes (5), to our
knowledge, this is the first report on the independent role
of IGFBP-3 in high-glucose-induced PTEC apoptosis.
Changes in cellular function by hyperglycemia that re-
sult in oxidative stress are crucial in the development and
progression of diabetic nephropathy. A unifying hypoth-
esis suggests that mitochondrial overproduction of ROS
initiates hyperglycemia-induced damage in the diabetic
kidney, leading to activation of four major biochemical
pathways:AGE formation, proteinkinaseC isoforms, and
flux through the polyol and hexosamine pathways. Each
of these pathways can contribute to the perpetuation of,
and in some cases initiate, cellular ROS generation (25).
Increased levels of ROS in hyperglycemia induce re-
nal cell apoptosis and diabetic nephropathy (30). Ver-
zola et al. (31) reported that hyperglycemia induces ap-
optotic changes in human tubular cells by increasing
oxidative stress. In this study, high glucose or IGFBP-3
overexpression increased oxidative stress, and siRNA:
IGFBP-3 abolished the increase in oxidative stress
caused by high glucose or IGFBP-3 overexpression, sug-
gesting that IGFBP-3 is involved in inducing oxidative
stress by high glucose in PTEC. On the other hand,
antioxidants decreased IGFBP-3 expressionandhigh-glu-
cose-induced apoptosis, and elevation of oxidative stress
by hydrogen peroxide increased IGFBP-3 expression, sug-
gesting thatoxidative stress increases IGFBP-3 expression.
In addition, ROS increase by high glucose or IGFBP-3
overexpression was significant at 6 h, whereas IGFBP-3
mRNAexpressionwas significantly increased at 12–48 h,
and apoptosis was most prominent at 72 h exposure to
high-glucose medium. Taken together, these results sug-
gest a positive loop between ROS and IGFBP-3, amplify-
ing ROS production and resulting in amplification of hy-
perglycemic damage (Fig. 5).
In the present study, treatment of siRNA:IGFBP-3 un-
der standard-glucose conditions also resulted in decreased
apoptosis. PTEC itself normally secrete IGFBP-3 in some
degree. It is possible that that inhibition of intrinsic
IGFBP-3 secretion by siRNA:IGFBP-3 resulted in subnor-
mal IGFBP-3 expression, resulting in decreased apoptosis.
Although it is well documented that IGFBP-3 promotes
apoptosis, the underlying mechanism of action remains
uncertain (7). Kim et al. (8) reported that IGFBP-3 induces
apoptosis through the activation of caspases, via a death
receptor-mediated pathway in breast cancer cells. It was
also demonstrated that IGFBP-3 significantly enhances
apoptosis by inhibiting nuclear factor-B activation in co-
lonic carcinoma-derived cell lines (32). However, the ac-
tual mechanism of IGFBP-3 action on PTEC apoptosis is
still unclear and needs to be elucidated.
In conclusion, this study found that high glucose in-
creases IGFBP-3 expression and induces oxidative stress
and apoptosis in PTEC. The results suggest that increased
IGFBP-3 expression by high glucose mediates high-glu-
cose-induced apoptosis in PTEC. We propose that ele-
vated levels of oxidative stress from high glucose increase
IGFBP-3 expression, thereby inducing apoptosis. In addi-
tion, increased expression of IGFBP-3 by high glucose in-
duces additional oxidative stress, whichmay result in am-
plification of hyperglycemic damage in PTEC.
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